Novo Nordisk and US-based Gilead Sciences have joined forces in a new clinical trial with the fatty liver disease NASH. Although the partnership only entails one study for now, it could kick off more collaborations in the field, says Novo's Head of Global Drug Discovery, who also anticipates similar agreements with other actors.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.